Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis. by Maan, Raoel et al.
1 
This article is protected by copyright. All rights reserved.  
Risk of infections during interferon-based treatment in patients with 
chronic HCV infection and advanced hepatic fibrosis1 
 
Raoel Maan
1
, Adriaan J. van der Meer
1
, Bettina E. Hansen
1
, Jordan J. Feld
2
, Heiner Wedemeyer
3
,  
Jean-François Dufour
4
, Frank Lammert
5
, Michael P. Manns
3
, Stefan Zeuzem
6
,  
Harry L.A. Janssen
1,2
,
 
Robert J. de Knegt
1
, Bart J. Veldt
1
 
 
1
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, 
Rotterdam, the Netherlands 
2
Toronto Centre for Liver Disease, Toronto Western & General Hospital, University Health Network, 
Toronto, Canada 
3
Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, 
Germany 
4
Hepatology, Department of Clinical Research, University of Bern, Bern, Switzerland 
5
Department of Medicine II, Saarland University Medical Center, Homburg, Germany 
6
Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany 
 
 
Email: r.maan@erasmusmc.nl; a.vandermeer@erasmusmc.nl; b.hansen@erasmusmc.nl; 
jordan.feld@uhn.ca; wedemeyer.heiner@mh-hannover.de; jean-francois.dufour@insel.ch; 
frank.lammert@uks.eu; manns.michael@mh-hannover.de; zeuzem@em.uni-frankfurt.de; 
harry.janssen@uhn.ca; r.deknegt@erasmusmc.nl; b.veldt@erasmusmc.nl  
 
Running head: Infections during HCV treatment 
                                                 
This article has been accepted for publication and undergone full peer review but has not been through the 
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version 
and the Version of Record. Please cite this article as doi: 10.1111/jgh.12929 
A
cc
ep
te
d 
A
rti
cl
e
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
67
16
1 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
2 
This article is protected by copyright. All rights reserved.  
Contact information 
R.Maan, MD 
Department of Gastroenterology and Hepatology 
Erasmus MC, University Medical Center Rotterdam 
‘s Gravendijkwal 230 
Room Ca 419 
3015 CE Rotterdam 
The Netherlands 
Tel: +31 10 703 4513 
Fax: +31 10 436 5916 
Email: r.maan@erasmusmc.nl 
 
Tables and figures: 5 tables and 3 figures (including 1 supplementary table and 1 
supplementary figure) 
Word count abstract: 254 words 
Word count manuscript: 3983 words 
 
List of abbreviations 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, 
confidence interval; DAAs, direct-acting antivirals; DM, diabetes mellitus; HCC, hepatocellular 
carcinoma; HCV, hepatitis C virus; IQR, interquartile range; OR, odds-ratio; PegIFN, pegylated 
interferon; RBV, ribavirin; SVR, sustained virological response 
 
 A
cc
ep
te
d 
A
rti
cl
e
3 
This article is protected by copyright. All rights reserved.  
 
Author contributions 
Study coordination and design, data collection, data analysis, writing of manuscript, approval of 
final version: RM, AJM 
Study coordination and design, data collection, critical review of the manuscript, approval of final 
version: BJV, RJK 
Data collection, critical review of the manuscript, approval of the final version: JJF, HW, J-FD, 
FL, MPM, SZ, HLAJ 
Statistical analysis, critical review of the manuscript, approval of final version: BEH 
RM, AJM, BEH, RJK and BJV had full access to all of the data in the study and take 
responsibility for the integrity of the data and the accuracy of the data analysis 
 
Financial support 
The study was not sponsored by third parties in the sense of industrial partners. The study was 
funded by the Foundation for Liver and Gastrointestinal Research in Rotterdam. This foundation 
was established in 1985 as an institution without purpose of financial gain and has the mission 
to stimulate scientific research in the field of diseases of the liver and the gastrointestinal tract. A 
major part of its activities are undertaken at the Erasmus MC in Rotterdam, the Netherlands. 
 
Disclosures 
Drs. Maan received financial compensation for consultancy activities from AbbVie. Drs van der 
Meer received financial compensation for lecture activities for MSD and Gilead. Dr. Feld 
received financial compensation for consultancy, and development of educational presentation 
activities from AbbVie, BMS, Merck, Gilead and Janssen and his institution received grants from 
Abbvie, Boehringer-Ingelheim, Gilead and Santaris. , and. Dr Wedemeyer received financial 
compensation for consultancy and/ or lecture activities from Roche, MSD, Abbott, Novartis, A
cc
ep
te
d 
A
rti
cl
e
4 
This article is protected by copyright. All rights reserved.  
Bristol Myers Squibb, and Gilead, and his institution received grants from Roche, Merck Sharpe 
& Dohme, Abbott, Novartis, Bristol Myers Squibb, and Gilead. Dr Manns received financial 
compensation for consultancy and/ or lecture activities from Roche, Bristol Myers Squibb, 
Gilead, Boehringer Ingelheim, Novartis, Merck, Janssen, and GlaxoSmithKline, and research 
grants from Roche, Gilead, Novartis, Boehringer Ingelheim, Bristol Myers Squibb, Merck, and 
Janssen. Dr Zeuzem received financial compensation for consultancy and/ or lecture activities 
from Abbott, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Gilead, Merck, Novartis, 
Roche, Santaris, Janssen, and Vertex. Dr Janssen received financial compensation for 
consultancy activities and/ or payment for lectures from Roche, Merck, Abbott, Santaris, 
Anadys, Medtronic, Tibotec, Bristol Myers Squibb, and Gilead, and his institution received 
grants from Roche, Merck, Abbott, Santaris, Anadys, Medtronic, and Tibotec. Dr. de Knegt 
reported that his institution received financial compensation for consultancy activities and/ or 
lecture activities from Merck, Janssen, Roche, Gilead, and Medtronic, and research grants from 
Merck and Roche. Dr Veldt received financial compensation for a board membership at 
GlaxoSmithKline and Janssen Therapeutics.  
 
ABSTRACT 
Background & Aims. Pegylated interferon-based treatment is still the backbone of current 
hepatitis C therapy and is associated with bone marrow suppression and an increased risk of 
infections. The aim of this retrospective cohort study was to assess the risk of infections during 
interferon-based treatment among patients with chronic HCV infection and advanced hepatic 
fibrosis and its relation to treatment-induced neutropenia.  
Methods. This cohort study included all consecutive patients with chronic HCV infection and 
biopsy-proven bridging fibrosis or cirrhosis (Ishak 4-6) who started treatment between 1990 and 
2003 in five large hepatology units in Europe and Canada. Neutrophil counts between 500/µL-
749/µL and below 500/µL were considered as moderate and severe neutropenia, respectively.  A
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Results. This study included 723 interferon-based treatments, administered to 490 patients. In 
total, 113 infections were reported during 88 (12%) treatments, of which 24 (21%) were 
considered severe. Only one patient was found to have moderate neutropenia and three 
patients were found to have severe neutropenia at the visit before the infection. Three hundred 
and twelve (99.7%) visits with moderate neutropenia and 44 (93.6%) visits with severe 
neutropenia were not followed by an infection. Multivariable analysis showed that cirrhosis (OR 
2.85, 95%CI 1.38-5.90, p=0.005) and severe neutropenia at the previous visit (OR 5.42, 95%CI 
1.34-22.0, p=0.018) were associated with the occurrence of infection, while moderate 
neutropenia was not. Among a subgroup of patients treated with PegIFN, severe neutropenia 
was not significantly associated (OR 1.63, 95%CI 0.19-14.2, p=0.660). 
Conclusions. In this large cohort of patients with bridging fibrosis and cirrhosis, infections 
during interferon-based therapy were generally mild. Severe interferon-induced neutropenia 
rarely occurred, but was associated with on-treatment infection. Moderate neutropenia was not 
associated with infection, suggesting that current dose reduction guidelines might be too strict. 
 
Keywords: Chronic hepatitis C; Antiviral treatment; Cirrhosis; Neutropenia; Infections; Side 
effects
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INTRODUCTION 
Hepatitis C virus (HCV) infection is a major cause of cirrhosis, hepatocellular carcinoma (HCC) 
and end-stage liver disease (1). It has been estimated that by 2030, 45% of the US patients 
chronically infected with HCV will have cirrhosis (2). Today, antiviral treatment efficacy among 
patients with cirrhosis is unsatisfactory (3-5). Although it is expected that even in this difficult-to-
treat subgroup of patients the sustained virological response (SVR) rates will improve 
substantially by using interferon-free regimes (6-8), pegylated interferon (PegIFN) and ribavirin 
(RBV) are still the backbone of antiviral therapy in most countries. In fact, due to the high costs 
of the new direct-acting antivirals (DAAs), PegIFN and RBV might remain the primary treatment 
option for many patients with chronic HCV infection around the globe. Treatment with PegIFN is, 
however, associated with major side-effects, of which bone marrow suppression and 
subsequent neutropenia is one of the most frequently reported. Out of concern for infections, 
product labels and guidelines currently advise physicians to reduce the dose of PegIFN when 
neutrophil counts drop below 750/µL and to stop PegIFN when neutrophil counts drop below 
500/µL (9, 10). This is largely based on prior experiences in oncology, where patients receiving 
chemotherapy showed an increased risk of infection when neutrophil counts dropped below 
500/µL, with the greatest risk below 100/µL (11). While patients undergoing interferon-based 
therapy are indeed more susceptible to bacterial and fungal infections, prior studies did not find 
these to be related to the treatment-induced neutropenia (12-15). Especially because interferon 
dose adjustments compromise antiviral treatment efficacy for patients with chronic HCV 
infection, it was suggested that the current guidelines regarding dose reductions might be too 
strict (16, 17). However, whereas patients with cirrhosis are considered to be 
immunocompromised and thus at the highest risk of infections, data regarding the relation 
between neutropenia and infections during interferon-based antiviral therapy within this 
population are scarce.  A
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PATIENTS AND METHODS 
Patients. The current study is based on all patients included in our previously described 
international, multicenter cohort (18). This cohort included all consecutive patients from 5 large 
hepatology units in Europe and Canada, who had chronic HCV infection and started an 
interferon-based treatment between 1990 and 2003. They all had histological proof of bridging 
fibrosis (Ishak fibrosis score 4) or cirrhosis (Ishak fibrosis score 5 or 6) (19). Patients co-infected 
with the human immunodeficiency virus or the hepatitis B virus were excluded, as well as 
patients with a history of decompensated liver disease. For the current study all consecutive 
treatment courses with available on-treatment data, including assessment of infection and 
laboratory results, were included. 
All charts were re-reviewed by a single investigator (RM) in order to collect detailed baseline 
and on-treatment data. Data were obtained on patient characteristics (age, gender, body mass 
index [BMI]), severity of liver disease (Ishak fibrosis score), presence of diabetes mellitus (DM), 
severe alcohol use and antiviral treatment (type of medication, treatment period, previous and 
current virological response). Furthermore, laboratory data (neutrophil count, platelet count, 
hemogblobin, albumin, bilirubin, aspartate aminotransferase [AST], alanine aminotransferase 
[ALT] and glucose) and virology data (HCV genotype, HCV RNA and anti-hepatitis B core 
antigen) were collected. The period within six months before treatment was considered as 
baseline. During antiviral treatment, all (Peg-)interferon and/or RBV dose reductions or 
treatment cessations were collected as well as all infectious episodes and all other adverse 
events.   
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and 
the principles of Good Clinical Practice. The study protocol was reviewed and approved by the 
ethics committee in the center of the primary investigators, which was the Erasmus Medical 
Center in Rotterdam, the Netherlands. Ethical approval in the participating centers was obtained 
according to the local regulations.  A
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Outcome measures. The primary outcome measure was the occurrence of infections during 
antiviral therapy or within two weeks after treatment cessation. Secondary outcome measures 
were on-treatment neutropenia and the severity of infections. 
Neutrophil counts from 500/µL to 749/µL were defined as moderate neutropenia, since 
interferon dose reductions are advised at these levels. Neutrophil counts below 500/µL were 
considered as severe neutropenia. Diabetes mellitus at baseline was defined by an elevated 
fasting glucose (>6.1 mmol/L), a positive glucose tolerance test or if patients were using anti-
diabetic medication.  
Infections were considered as all the episodes of clinically suspected infection according to the 
treating physician, when antibiotic therapy was prescribed or when there was evidence of an 
infection (radiology, positive culture). Severe infections were defined as infections resulting in 
death, hospital admission or treatment discontinuation. All other infections were defined as mild.  
 
Statistical analyses. Continuous variables were summarised as median (interquartile range 
[IQR]) and categorical variables as frequencies (percentages). Comparisons between groups 
were performed using X2 test for categorical variables or the Mann-Whitney U test for 
continuous variables.  
The dynamics of neutrophil counts during treatment for different groups were studied with a 
repeated measurement model. A restricted cubic spline was fitted per group and to take into 
account multiple measurements per patient during treatment a model with random intercept and 
slope was applied.  
Logistic regression was used to assess which baseline factors were associated with the 
occurrence of infections during antiviral therapy. Age, sex, cirrhosis, DM and variables with a p-
value of ≤ 0.2 in univariable analyses were included in multivariable analyses. Adjusting for 
multiple measurements within a patient, the association between on-treatment neutrophil counts A
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and succeeding infectious events was assessed. By using a backward stepwise method we 
selected the variables significantly associated with infections and included these in the final 
model. Akaike’s Information Criteria were used to select the best model. A sensitivity analysis 
was performed among only those patients treated with PegIFN-based regimens, since standard 
interferon is not used nowadays. Another sensitivity analysis was performed among only those 
patients with cirrhosis, since these patients are at the highest risk of infection. 
The cumulative incidence of infections was assessed using the Kaplan-Meier method. The log-
rank test was applied to compare patients with bridging fibrosis and cirrhosis.  
A p-value <0.05 was considered statistically significant and all statistical tests were two-tailed. 
The significance level of interactions was set at 0.01 in order to correct for multiple testing (18). 
PASW statistics 21.0 for Windows (SPSS, IBM, Armonk, New York, USA) and SAS 9.3 were 
used.
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RESULTS 
Patients. Overall, 546 patients with chronic HCV infection and bridging fibrosis or cirrhosis 
started interferon-based antiviral therapy between 1990 and 2003. In 490 (90%) patients 
detailed on-treatment data were available to assess the occurrence of infections during at least 
one interferon-based regimen. Of the 361 (74%) patients without SVR, 174 received at least 
one subsequent antiviral treatment regimen. Overall, 723 treatment courses could be included 
in the analyses. Table 1 summarizes the baseline characteristics of the patients at their first 
included treatment. Median age was 49 years (IQR 43–56), 336 (69%) patients were male and 
372 (76%) presented with cirrhosis.     
 
Neutropenia and dose of interferon. The median neutrophil count prior to the start of all 
treatment courses was 3000/µL (IQR 2400–3900). Median time between visits was 2 weeks 
(IQR 1–4 weeks). During therapy the median neutrophil count decreased to a nadir of 1200/µL 
(IQR 800–1700) in a median time of 11 weeks (IQR 4–22). Patients receiving PegIFN had a 
lower median nadir neutrophil count as compared to patients receiving standard interferon 
(1000/µL [IQR 700–1400] versus 1400/µL [IQR 1000–2000], p<0.001), whereas baseline 
neutrophil counts did not differ between these groups (p=0.729). Figure 1 shows the course of 
neutrophil counts during treatment. During 88 (12%) treatment courses moderate neutropenia 
occurred at least once, and during 23 (3%) treatment courses severe neutropenia occurred at 
least once. Because of neutropenia, the (Peg-)interferon dose was reduced during 58 (8%) 
treatment courses and 3 (<1%) treatments were discontinued. 
 
Infections. In total, 113 infections were reported during 88 (12%) treatments among 81 (17%) 
patients. Table 2 summarises the type of infections. Dermatological infections were most 
common (24%), followed by upper respiratory tract infections (20%) and urinary tract infections 
(18%). None of the patients were diagnosed with spontaneous bacterial peritonitis during A
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treatment. Median time until the first infection was 12 weeks (IQR 6–24). Time until infection 
was not significantly different for mild or severe infections (p=0.648). Twenty-four infections 
among 23 (3.2%) patients were defined as severe. Treatment was discontinued due to infection 
in 7 patients and 23 hospital admissions due to an infection were reported. The median duration 
of admission was 9 days (IQR 3–12). None of the patients died as a result of an on-treatment 
infection. During 92 (81%) of the infections, antibiotic therapy was prescribed. 
 
Neutropenia and infections. Eleven patients (1.5%) had a baseline neutrophil count below 
1500/µL, of which ten patients had a grade 2 neutropenia (i.e. neutrophil count <1500 /µL) and 
only one patients had a grade 3 neutropenia (i.e. neutrophil count <1000/µL). Three of these 
patients needed a dose reduction due to neutropenia, of which one patient discontinued due to 
side effects, and one of these patients needed dose reductions due to thrombocytopenia. In 
only one patient an infection was reported, which was severe. This patient required hospital 
admission for 23 days due to a Staphylococcus aureus bacteremia following cellulitis. The 
infection resolved with intravenous antibiotics, while interferon and RBV were continued.   
For 81 infections (72%) the neutrophil count at the visit prior to the infection was available. 
Median neutrophil count at the visit prior to an infection was 1740/µL (IQR 1300–2650). The 
median neutrophil count at the previous visit was not different for mild and severe infections 
(p=0.399). Only one patient was found to have moderate neutropenia (neutrophil count of 
690/µL) and three patients were found to have severe neutropenia (neutrophil counts of 300/µL, 
330/µL and 390/µL) at the visit before the infection. Three hundred and twelve (99.7%) visits 
with moderate neutropenia and 44 (93.6%) visits with severe neutropenia were not followed by 
an infection. Patients who underwent a dose reduction of (Peg-)interferon did not experience 
less infections, compared to patients who did not undergo a dose reduction (10.8% vs 10.6%, 
p=1.00). During nine treatment courses, dose reductions were performed after an infection was 
reported. A
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Table 3 summarizes the results of univariable logistic analysis, which showed that female 
gender (OR 1.58, 95%CI 1.01–2.47, p=0.044), the presence of cirrhosis (OR 2.14, 95%CI 1.19–
3.85, p=0.011) and number of weeks on treatment (OR 1.01, 95%CI 1.00–1.02, p=0.032) were 
significantly associated with infection. While moderate neutropenia at the visit prior to infection 
was not significantly associated (OR 0.19, 95%CI 0.03–1.40, p=0.103) with infection, severe 
neutropenia at the previous visit was (OR 4.25, 95%CI 1.21–14.9, p=0.024).  
Multivariable logistic analyses, adjusted for age, gender, DM, number of weeks on treatment 
and type of interferon, showed that cirrhosis (OR 2.85, 95%CI 1.38-5.90, p=0.005) and severe 
neutropenia at the visit prior to the infection (OR 5.42, 95%CI 1.34-22.0, p=0.018) were 
independently associated with infections. The interaction terms between the variables in the 
final model were not statistically significant.  
In a sensitivity analysis including only the 356 (49%) PegIFN-based treatment courses among 
292 patients, during which 71 infections were reported, severe neutropenia at the visit prior to 
infection was not significantly associated (OR 1.63, 95%CI 0.19-14.2, p=0.660). In this analysis 
cirrhosis (OR 3.22, 95%CI 1.16-8.95, p=0.025) was the only factor associated with infection. 
Table 4 shows the variables associated with severe infection during antiviral treatment. After 
adjustment for age and cirrhosis, female gender (OR 3.94, 95%CI 1.54-10.1, p=0.004) and DM 
(OR 3.84, 95%CI 1.52-9.70, p=0.004) were associated with the occurrence of severe infections. 
Figure 2 illustrated the infection rates according to the presence of cirrhosis or DM.
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DISCUSSION 
In this large cohort study, infections which occurred during interferon-based antiviral 
therapy were generally mild. The percentage of 12% of treatment courses complicated by 
infections is in line with previous studies reporting an infection rate of 4-23% (12, 14, 20, 21). 
Moderate (Peg-)interferon-induced neutropenia was not associated with infection, whereas 
severe neutropenia was. However, a sensitivity analysis among patients treated with PegIFN 
could not confirm this. Furthermore, approximately 94% of the visits of patients with severe 
neutropenia were not followed by an infection. Cirrhosis and diabetes were important risk 
factors for the occurrence and severity of infection. 
This real-life study was not limited by strict interferon dose modification rules which are 
used in clinical trials and thereby allows for assessment of lower neutrophil counts in relation to 
infections. Severe neutropenia occurred during only 3% of antiviral treatment regimens and only 
four (17%) of these treatment courses with severe neutropenia were complicated by an 
infection. When only PegIFN-based regimens were considered, the association between severe 
neutropenia and occurrence of infections was not statistically significant. This is in line with the 
findings of Antonini et al. (21) who showed that neither the presence nor duration of neutropenia 
was associated with the occurrence of infections among 319 chronic HCV-infected patients 
treated with PegIFN and RBV. This was confirmed by another retrospective study among 321 
PegIFN and RBV treated patients, as also in this study on-treatment neutropenia and its 
duration were not associated with infectious episodes (12). The IDEAL study is the largest 
clinical study to date, which prospectively assessed the role of PegIFN-induced cytopenias on 
the occurrence of infections (20). Again, no association between nadir neutrophil count and 
occurrence of infection was found. The authors did report, however, that the nadir lymphocyte 
count was associated with infectious episodes. Because the nadir lymphocyte count was 
analysed rather than the lymphocyte count at the most recent visit prior to infection, it remains A
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difficult to determine causality and to translate this finding into clinical recommendations with 
respect to the dose of PegIFN. In our cohort, lymphocyte counts were not available as these are 
not collected during antiviral therapy in daily practice. 
In contrast to our cohort, the above described studies included a relatively low number of 
patients with advanced fibrosis (11-30%) and did not show results for this subgroup specifically. 
We found that patients with cirrhosis more frequently experienced infections during interferon-
based therapy as compared to those with bridging fibrosis. Roomer et al. (12) also described a 
higher rate of infectious episodes among the 68 (21%) patients with cirrhosis included in their 
study, and from other cohorts, similar results were obtained with odds ratios ranging from 2.7-
4.9 (12-15). Triple therapy regimens with DAAs were not included in our study and often reduce 
treatment duration to 12 or 24 weeks (22-24). Shortened PegIFN therapy could prevent 
infections, as we found a linear infection rate during treatment with a median of 12 weeks from 
initiation of therapy to the occurrence of an infection (Supplementary figure 1). However, first 
real-world data regarding the addition of telaprevir or boceprevir to PegIFN and RBV therapy 
indicate a substantially elevated risk of severe infections among patients with cirrhosis, likely 
because patients with advanced cirrhosis who would have met stopping rules with PegIFN and 
ribavirin alone, were able to achieve viral suppression and stay on therapy longer, thus 
increasing their risk of infection (25). Cirrhosis is considered an immunocompromised state 
which may lead to a variety of infections, also outside of the scope of interferon-based therapy 
(26). Translational studies have suggested that patients with cirrhosis have impaired neutrophil 
function, limiting the first immunological defence against bacterial pathogens (27, 28).  
As this cohort study included solely patients treated with an interferon-based regimen, it 
lacks a control group of untreated cirrhotic patients. However, a previous study among cirrhotic 
patients awaiting liver transplantation, found that there was a higher incidence of infections in 
the group that was treated with PegIFN and RBV compared to the matched control group that 
did not receive treatment, respectively 13 events and 2 events (p=0.012) (29). This study A
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indicated that PegIFN-based antiviral treatment increases the risk of bacterial infections in a 
cirrhotic population. Although apparently not through a reduction in neutrophil counts, infectious 
episodes are more frequently encountered during the use of interferon-based therapy. The 
mechanisms for this association are, however, not well understood. It has been hypothesized 
that PegIFN alters neutrophil function, but limited data are available (30). Others have 
suggested that PegIFN boosts other factors among cirrhotic patients which facilitate infections, 
such as bacterial translocation, dysfunction of the reticuloendothelial system and reduction of 
serum and ascitic fluid complement levels (31). Thus, an impaired function of the immune 
system might be responsible for the increased infection rate during interferon based therapy.   
Current recommendations regarding PegIFN dose reductions are based on experience 
among cancer patients receiving chemotherapy (11). In this situation, however, other 
mechanisms such as mucosal damage and hampered organ function caused by the underlying 
disease play important roles in the susceptibility for infections as well. Dose reductions due to 
neutropenia may need to be carefully considered as long as the neutrophil counts remain stable 
between 500 and 750µ/L. Dose reductions reduce the chance to attain SVR, which is likely to 
affect clinical outcome (16, 17, 32). A study among African American and Caucasian American 
patients, in whom dose reductions were not undertaken until the neutrophil count dropped below 
500/µL, did not report a higher rate of infections than expected (33). Our study further suggests 
that dose reductions could not prevent infectious episodes during antiviral therapy as the 
number of patients who underwent a dose reduction of (Peg-)IFN did not experience less 
infections (10.8% vs 10.6%). This should be interpreted with caution as dose reductions were at 
the discretion of the treating physicians and the number of infections could be higher if these 
dose reductions were not applied. The treating physicians could have applied dose reductions 
only to those patients that had a higher initial risk for infectious events. Due to its retrospective 
character, one could not really conclude that reductions of IFN could not affect the occurrence 
of infections. Ideally, one would design a randomized controlled trial with one group of patients A
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undergoing dose reductions and the other group continuing the dose despite low neutrophil 
counts (or other haematological adverse events). Such studies are however hardly feasible. 
One could also debate whether dose reductions were performed too late. Unfortunately we were 
unable to assess this issue. Dose reductions were not performed according to the guidelines, 
making it impossible to conclude on timing of dose reductions. Furthermore, dose reductions 
were also performed for other reasons than neutropenia. 
Our finding of an association between DM and more severe infection was not 
unexpected. Higher infection rates among diabetic patients could be explained by vascular 
insufficiency, depressed leucocyte and natural killer cell function, as well as impaired antioxidant 
systems involved in antibacterial activity (34, 35). Others have previously shown that the risk of 
infections during PegIFN-based therapy was around two to three fold higher among patients 
with chronic HCV infection and DM (12, 15). 
The association of female gender and the occurrence of severe infection was also seen 
in the largest prospective study that assessed the risk for infections during antiviral treatment 
(20). In this study, they found an increased incidence of urinary tract infections and Candida 
infections, partly explaining the finding. Furthermore, they also found  an increased incidence of 
respiratory tract infections among women. This was also the case in our study, where more 
women required hospital admission due to respiratory tract infections. There was no higher 
incidence of infections of the urinary tract. Although the underlying mechanism of our findings is 
not clear, clinicians should be aware of a possible increased risk for severe infection among 
women treated with PegIFN and RBV. 
A limitation of our study is that, due to its retrospective character, not all infections may 
have been reported. However, it is unlikely that severe infections, which are clinically most 
relevant, were missed. Also, there was heterogeneity in the treatment regimens administered, 
varying from interferon monotherapy to combination therapy with PegIFN and RBV. Because A
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neutrophil counts showed deeper declines with PegIFN, a sensitivity analysis was performed 
including only PegIFN-containing regimens.  
In conclusion, patients with chronic HCV infection and bridging fibrosis and cirrhosis 
undergoing interferon-based therapy experience generally mild infections. Patients with cirrhosis 
are at elevated risk of interferon-associated infections and among patients with DM the course of 
infection seems to be more severe, indicating these groups should be carefully monitored. 
Although on-treatment severe neutropenia (<500/µL) might be associated with an elevated risk of 
infection, such deep declines in neutrophils do not frequently occur during PegIFN-based 
therapy. Furthermore this finding could not be confirmed among a subgroup of patients treated 
with PegIFN, which is used in current daily practice. Moderate neutropenia was not associated 
with an increased infection rate, suggesting that dose reductions due to neutropenia may need to 
be carefully considered as long as the neutrophil counts remain stable between 500 and 750µ/L.  
Current guidelines regarding PegIFN dose reductions might be too strict and may unnecessarily 
compromise the virological efficacy of interferon-based therapy. 
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Legends to the figures 
 
Figure 1. 
Dynamics of the neutrophil counts during treatment. Panel A shows the dynamics of neutrophil 
counts among all patients. Panel B shows the dynamics of neutrophil counts among patients 
with bridging fibrosis and cirrhosis. Panel C shows the dynamics of neutrophil counts among 
patients treated with standard interferon and pegylated interferon (p<.001).  
 
Figure 2. 
The bars represent the percentage of treatments with at least one mild or severe infection 
among specific subgroups of patients based on the presence of cirrhosis and diabetes mellitus. 
Fifteen infections were reported among patients that had both cirrhosis and diabetes mellitus, of 
which 10 were mild infections and 5 were severe infections.   
 
 
Supplementary figure 1. 
 
Kaplan-Meier curve showing the occurrence of infection within the first 30 weeks of treatment 
within two groups based on the presence of cirrhosis. 
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Table 1. Baseline characteristics at first registered treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Abbreviations: PegIFN ; pegylated interferon 
b. Medians are presented as number, (IQR, interquartile range). Numbers are presented as n, (percentage of the whole 
group) 
 
Variable (missing cases [%])  
Patients 
(n=490) 
Male 336 (69%)  
Age, in years  49 (43–56) 
BMI, in kg/m
2 
*  26.5 (23.7–29.4) 
HCV genotype 
1 
2 
3 
4 
Other/ unknown 
 
316 (65%) 
46 (9%) 
79 (16%) 
23 (5%) 
26 (5%) 
Treatment naïve 397 (81%) 
Cirrhosis  372 (76%) 
Fibrosis score  
Ishak 4 
Ishak 5 
Ishak 6 
 
118 (24%) 
98 (20%) 
274 (56%) 
Neutrophil count per µL *  3040 (2500–3900) 
Platelet count, in 10
9
/L 146 (108–197) 
Albumin, in g/L * 42 (39–44) 
Bilirubin, in μmol/L * 13 (10–19) 
Treatment with PegIFN  201 (41%) 
Treatment duration, in weeks 26 (21–48) 
Diabetes mellitus  64 (13%) 
Alcohol abuse ever * 109 (22%) 
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c. Variables with an asterisk (*) had ≥10% missing values 
Table 2. Type of infections 
 
a. Data presented as number, (percentage of the total number of infections) 
b. Other infections included a case of endocarditis (severe), dental and eye infections 
c. Severe infection was defined as infection requiring hospital admission or treatment discontinuation  
Type of infection n (%) Severe infection (%)
c
 
Urinary tract 20 (18%) 3 (3%) 
Upper respiratory tract  22 (20%) 2 (2%) 
Pulmonary 15 (13%) 6 (5%) 
Dermatological  27 (24%) 8 (7%) 
Gastrointestinal 3 (3%) 2 (2%) 
Oral  12 (11%) 1 (1%) 
Other
b
 14 (12%) 2 (2%) 
Total  113 (100%) 24 (21%) 
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Table 3. Logistic regression analysis for infection 
Variable 
 
Univariable 
OR (95% CI) 
p-value Multivariable 
OR (95% CI) 
p-value Multivariable (PegIFN 
only*)  
OR (95% CI) 
p-value 
Age 1.02 (1.00-1.04) 0.075 1.02 (0.99-1.05) 0.296 1.02 (0.99-1.06) 0.218 
Female gender 1.58 (1.01-2.47) 0.044 1.67 (0.95-2.94) 0.077 1.03 (0.52-2.10) 0.913 
BMI 1.03 (0.98-1.07) 0.263     
Cirrhosis at baseline 2.14 (1.19-3.85) 0.011 2.85 (1.38-5.90) 0.005 3.22 (1.16-8.95) 0.025 
DM at baseline 1.58 (0.96-2.59) 0.073 1.48 (0.78-2.81) 0.224 1.17 (0.53-2.56) 0.694 
Weeks on treatment 1.01 (1.00-1.02) 0.032 1.01 (0.99-1.02) 0.322   
Type of interferon (PegIFN vs 
standard interferon) 
1.38 (0.88-2.16) 0.155 0.80 (0.45-1.41) 0.435   
Moderate neutropenia at 
previous visit (500-749/µL) 
0.19 (0.03-1.40) 0.103     
Severe neutropenia at 
previous visit (<500/µL) 
4.25 (1.21-14.9) 0.024 5.42 (1.34-22.0) 0.018 1.63 (0.19-14.2) 0.660 
Absolute drop in neutrophil 
count, per 1/µL 
0.98 (0.70-1.38) 0.924     
Relative drop in neutrophil 
count, per 1/µL
d
 
1.01 (0.98-1.03) 0.620     
Platelet count ≤ 100 * 10
9
/L 0.86 (0.49-1.50) 0.589     
Albumin < 35 g/L 1.36 (0.59-3.15) 0.471     
a. Abbreviations: BMI, body mass index; DM, Diabetes mellitus; PegIFN, pegylated interferon 
b. All analyses were corrected for multiple measurements within a patient 
c. * PegIFN based therapy, including 25 treatments with PegIFN monotherapy 
d. Relative neutrophil drop is defined as the absolute drop in neutrophil count / baseline neutrophil count 
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Table 4. Logistic regression analysis for severe infection* 
Variable# 
 
Univariable 
OR (95% CI) 
p-value Multivariable 
OR (95% CI) 
p-value 
Age 1.01 (0.97-1.06) 0.572 1.00 (0.95-1.05) 0.942 
Female gender 3.63 (1.41-9.34) 0.008 3.94 (1.54-10.1) 0.004 
BMI 0.98 (0.87-1.11) 0.759   
Cirrhosis at baseline 1.47 (0.50-4.36) 0.484 1.23 (0.40-3.77) 0.721 
DM at baseline 3.04 (1.29-7.20) 0.011 3.84 (1.52-9.70) 0.004 
Weeks on treatment 0.89 (0.72-1.10) 0.280   
Type of interferon (PegIFN vs 
standard interferon) 
0.80 (0.34-1.87) 0.600   
Baseline neutropenia 1.02 (0.76-1.36) 0.920   
Platelet count ≤ 100 * 10
9
/L 1.52 (0.58-4.00) 0.396   
Albumin < 35 g/L 2.45 (0.69-8.65) 0.164   
a. Abbreviations: BMI, body mass index; DM, Diabetes mellitus; PegIFN, pegylated interferon 
b. All analyses were corrected for multiple measurements within a patient 
c. * Severe infections were defined as infections were treatment was discontinued or when admission was needed  
d. # There were too few cases with moderate (n=1) or severe (n=1) neutropenia and severe infection to include these 
variables in the analysis. 
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